วัคซีนโควิด-19
แหล่งข้อมูลอื่น

↑  
Wadman, M (November 2020). "The long shot". Science. 370 (6517): 649–53. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120.
↑  
Wadman, M (2020-12-28). "Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays". Science. doi:10.1126/science.abg3441.
↑  
Parekh, N (2020-07-24). "Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19". เก็บจากแหล่งเดิมเมื่อ 2020-11-22. สืบค้นเมื่อ 2020-07-24.
↑  
Chung, YH; Beiss, V; Fiering, SN; Steinmetz, NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". ACS Nano. 14 (10): 12522–37. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.
↑  
Moitra, P; Alafeef, M; Dighe, K; Frieman, MB; Pan, D (June 2020). "Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles". ACS Nano. 14 (6): 7617–27. doi:10.1021/acsanm.0c01978. PMC 7482545. PMID 32437124.
↑  "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom - Full Text View - ClinicalTrials.gov". สืบค้นเมื่อ 2020-11-22.
↑  
"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2". ClinicalTrials.gov. สืบค้นเมื่อ 2020-12-30.
↑  "The study to check the safety and immune response of (Covid-19 vaccine) COVOVAX in adults". ctri.nic.in. Clinical Trials Registry- India. 2021-02-25. สืบค้นเมื่อ 2021-06-15.{{cite web}}:  CS1 maint: url-status (ลิงก์)
↑  "Covovax trials begin in India, launch hopefully in September: Adar Poonawalla". India Today. 2021-03-27. สืบค้นเมื่อ 2021-03-28.
↑  Keech, C; Albert, G; Cho, I; Robertson, A; Reed, P; Neal, S; Plested, JS; Zhu, M; Cloney-Clark, S; Zhou, H; Smith, G; Patel, N; Frieman, MB; Haupt, RE; Logue, J; McGrath, M; Weston, S; Piedra, PA; Desai, C; Callahan, K; Lewis, M; Price-Abbott, P; Formica, N; Shinde, V; Fries, L; Lickliter, JD; Griffin, P; Wilkinson, B; Glenn, GM (September 2020). "Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The New England Journal of Medicine. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.
↑  "Trudeau Signs Deal to Make Novavax Covid-19 Vaccine in Canada". Bloomberg.com. 2021-02-02. สืบค้นเมื่อ 2021-04-01.
↑  "EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)". European Medicines Agency (EMA) (Press release). 2020-12-01. สืบค้นเมื่อ 2021-02-04.
↑  
"Ukraine secures 12 million AstraZeneca, Novavax COVID-19 vaccine doses". Reuters. 2021-02-05. สืบค้นเมื่อ 2021-02-24.
↑  
"COVID-19: Ukraine set to launch coronavirus vaccination programme". euronews. 2021-02-08. สืบค้นเมื่อ 2021-02-24.
↑  "AstraZeneca and Novavax COVID Vaccines: What We Know So Far". NBC Chicago. สืบค้นเมื่อ 2021-04-01.
↑  "UK secures deal to bottle 60m Novavax vaccine doses in the North East". CityAM. 2021-03-29. สืบค้นเมื่อ 2021-04-01.
↑  "Novavax COVID vaccine takes first step toward Australian approval". Regulatory Affairs Professionals Society (RAPS). สืบค้นเมื่อ 2021-04-01.
↑  biopharma-reporter.com. "New Zealand secures COVID-19 vaccines from Novavax and AstraZeneca". BioPharma-Reporter. สืบค้นเมื่อ 2021-04-01.
↑  "S.Korea says Novavax, Sputnik V COVID-19 vaccines submitted for regulatory approval". 2021-04-29.
↑  Magsambol, Bonz (2021-08-06). "Novavax applies for emergency use of its COVID-19 vaccine in Philippines". Rappler.
1 2  "Novavax seeks COVID-19 vaccine use in India, Indonesia, the Philippines ahead of U.S." CP24. 2021-08-05. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-05. สืบค้นเมื่อ 2021-08-06.
↑  
"Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". ClinicalTrials.gov. 2021-05-27. NCT04904549. สืบค้นเมื่อ 2021-05-28.
↑  
"Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/06/034442. สืบค้นเมื่อ 2021-08-03.
↑  "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. สืบค้นเมื่อ 2021-03-24.
↑  "Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país" [VAT00008 Study Participant Card: Central Example for Country-Level Adaptation] (PDF). incmnsz.mx. Salvador Zubirán National Institute of Health Sciences and Nutrition. 2021-04-15. คลังข้อมูลเก่าเก็บจากแหล่งเดิม (PDF)เมื่อ 2021-06-30. สืบค้นเมื่อ 2021-10-09.
↑  "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". ClinicalTrials.gov. 2020-09-03. NCT04537208. สืบค้นเมื่อ 2021-03-11.
↑  "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". ClinicalTrials.gov. 2021-02-21. NCT04762680. สืบค้นเมื่อ 2021-03-11.
↑  "Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine". GSK (Press release). สืบค้นเมื่อ 2021-04-01.
↑  "Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine". GSK (Press release). สืบค้นเมื่อ 2021-04-01.
↑  "U.S. Likely to Get Sanofi Vaccine First If It Succeeds". Bloomberg.com. 2020-05-13. สืบค้นเมื่อ 2021-04-01.
↑  "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News Online. 2020-07-29. สืบค้นเมื่อ 2021-04-01.
1 2  "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov, US National Library of Medicine. 2020-06-26. NCT04449276. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  "COVID-19". CureVac. สืบค้นเมื่อ 2020-12-21.
↑  
"A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19". ClinicalTrials.gov. 2020-12-03. NCT04652102. สืบค้นเมื่อ 2021-07-22.
↑  
"A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19". ClinicalTrials.gov. 2020-12-19. NCT04674189. สืบค้นเมื่อ 2021-03-23.
↑  
"A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19". ClinicalTrials.gov. 2021-04-09. NCT04838847. สืบค้นเมื่อ 2021-04-26.
↑  
"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19". ClinicalTrials.gov. 2021-04-26. NCT04860258. สืบค้นเมื่อ 2021-04-26.
↑  
"COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)". ClinicalTrials.gov. 2021-04-19. NCT04848467. สืบค้นเมื่อ 2021-06-18.
↑  "COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 2020-11-19. 2020-003998-22. สืบค้นเมื่อ 2020-12-19.
↑  
"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 2020-08-17. NCT04515147. เก็บจากแหล่งเดิมเมื่อ 2020-08-23. สืบค้นเมื่อ 2020-08-28.
↑  "EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)". European Medicines Agency (EMA) (Press release). 2020-12-01. สืบค้นเมื่อ 2021-02-12.
↑  "CureVac seeks Covid-19 shot approval in Switzerland". Swissinfo. 2021-04-20. สืบค้นเมื่อ 2021-04-22.
↑  
"GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine". PMLive (ภาษาอังกฤษ). 2020-11-13. สืบค้นเมื่อ 2020-11-16.
↑  
"Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate" (Press release). GlaxoSmithKline. 2021-03-16. สืบค้นเมื่อ 2021-04-13.
↑  
Chander, Vishwadha (2020-07-14). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. เก็บจากแหล่งเดิมเมื่อ 2020-11-01. สืบค้นเมื่อ 2020-07-14.
↑  Medicago (2020-11-18). "Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older".
↑  
Ward, Brian J.; Gobeil, Philipe; Séguin, Annie; Atkins, Judith; Boulay, Iohann; Charbonneau, Pierre-Yves; Couture, Manon; D'Aoust, Marc-André; Dhaliwall, Jiwanjeet; Finkle, Carolyn; Hager, Karen (2020-11-06). "Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants". MedRxiv (ภาษาอังกฤษ): 2020.11.04.20226282. doi:10.1101/2020.11.04.20226282. S2CID 226255762.
↑  
Medicago (2020-10-21). "A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age".
↑  "Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years". ClinicalTrials.gov. 2020-06-29. NCT04450004. สืบค้นเมื่อ 2021-03-17.
↑  "Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine". Medicago (Press release). คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-03-23. สืบค้นเมื่อ 2021-04-01.
↑  
"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 2020-12-31. สืบค้นเมื่อ 2021-01-11.
↑  
"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". clinicaltrials.gov. U.S. National Library of Medicine. 2020-12-30. สืบค้นเมื่อ 2021-01-11.
↑  
"Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001" (Press release). Valneva. 2021-04-21. สืบค้นเมื่อ 2021-04-22.
↑  "Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)". ClinicalTrials.gov. 2021-04-29. NCT04864561.
↑  "Immunogenicity of VLA2101 Compared to VLA2001". ClinicalTrials.gov. 2021-07-09. NCT04956224.
↑  
"Evaluating COVID-19 Vaccination Boosters". isrctn.com. ISRCTN Registry. สืบค้นเมื่อ 2021-06-06.
↑  Balfour, Hannah (2021-01-15). "Valneva may provide Europe with the only inactivated virus vaccine for COVID-19". European Pharmaceutical Review.
↑  "Valneva Seeks UK Approval for Covid-19 Vaccine". Dow Jonese News Wire. 2021-08-23. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-10-09. สืบค้นเมื่อ 2021-10-09.
↑  "VN starts injection of homegrown COVID-19 vaccine in first-stage human trial". Viet Nam News. 2020-12-17.
↑  
"Draft landscape and tracker of COVID-19 candidate vaccines". World Health Organization (WHO). 2021-02-26.
↑  
"How much does first Made-in Vietnam COVID-19 vaccine cost?". Voice of Vietnam. 2020-12-11.
↑  
"Local Nanocovax vaccine's phase 3 trial to begin next week". vietnamnet.vn. 2021-05-26. สืบค้นเมื่อ 2021-05-28.
↑  
"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19". ClinicalTrials.gov. 2021-06-11. NCT04922788. สืบค้นเมื่อ 2021-06-11.
↑  Le, C; Thu, A (2021-02-26). "Vietnam enters second phase of Covid-19 vaccine trials". VnExpress.
↑  Onishi, Tomoya (2021-06-15). "Vietnam homegrown COVID vaccine heads for full approval by year-end". Nikkei Asia.
↑  
"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers". ClinicalTrials.gov. 2021-02-26. NCT04773067. สืบค้นเมื่อ 2021-03-20.
↑  
"A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine". ClinicalTrials.gov. 2020-12-24. NCT04683224. สืบค้นเมื่อ 2021-03-20.
↑  Liao, George (2021-06-27). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. สืบค้นเมื่อ 2021-07-08.
↑  "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine". ClinicalTrials.gov. 2020-09-11. NCT04545749. สืบค้นเมื่อ 2021-03-20.
↑  Strong, Matthew (2021-06-30). "Taiwan's United Biomedical applies for COVID vaccine EUA". Taiwan News.
↑  "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 2021-06-28. NCT04942405. สืบค้นเมื่อ 2021-06-29.
↑  
"Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)". ClinicalTrials.gov. 2020-12-31. NCT04691947. สืบค้นเมื่อ 2021-03-21.
↑  
"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". ClinicalTrials.gov. 2021-04-01. NCT04824391. สืบค้นเมื่อ 2021-04-04.
↑  "A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)". ClinicalTrials.gov. 2021-05-27. NCT04904471. สืบค้นเมื่อ 2021-05-28.
↑  
"Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". ClinicalTrials.gov. 2020-08-28. NCT04530656. สืบค้นเมื่อ 2021-03-20.
↑  
"A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". ClinicalTrials.gov. 2020-11-23. NCT04640402. สืบค้นเมื่อ 2021-03-20.
↑  
"Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". ClinicalTrials.gov. 2021-01-22. NCT04718467. สืบค้นเมื่อ 2021-03-20.
↑  
"SCB-2019 as COVID-19 Vaccine". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-05-28. NCT04405908. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 2020-06-20. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-06-25.
↑  
"About Us". Clover Biopharmaceuticals. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-01.
↑  
"A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)". ClinicalTrials.gov. 2020-12-17. NCT04672395. สืบค้นเมื่อ 2021-03-10.
↑  "Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate". Dynavax. 2021-03-24. สืบค้นเมื่อ 2021-06-07.
↑  "A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases". ClinicalTrials.gov. 2021-08-19. NCT05012787. สืบค้นเมื่อ 2021-08-19.
↑  "Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults in China". ClinicalTrials.gov. 2021-07-08. NCT04954131. สืบค้นเมื่อ 2021-07-08.
↑  "A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above". Chinese Clinical Trial Register (Registry). 2020-06-24. ChiCTR2000034112. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-06.
↑  "Company introduction". Walvax Biotechnology. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-01.
↑  
"A Phase III Clinical Study to Evaluate the Protective Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate in Population Aged 18 Years and Above". chictr.org.cn. Chinese Clinical Trial Registry. สืบค้นเมื่อ 2020-04-17.
↑  "A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine in Population Aged 18 Years and Older". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-23. สืบค้นเมื่อ 2021-07-21.
↑  "A Phase I/II Clinical Trial to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine in Healthy Population Aged 60 Years and Older". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-23. สืบค้นเมื่อ 2021-08-02.
↑  "A Phase II clinical trial to evaluate the immunogenicity and safety of different doses of a novel coronavirus pneumonia (COVID-19) mRNA vaccine in population aged 18-59 years". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-03-16. สืบค้นเมื่อ 2021-03-20.
↑  
"Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)". ClinicalTrials.gov. 2021-06-29. NCT04944368. สืบค้นเมื่อ 2021-06-29.
↑  "Vaxine". เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-01.
↑  ""Spikogen", A Joint Venture Between Vaxine And Cinnagen". Vaxine. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-11. สืบค้นเมื่อ 2021-10-09.
↑  
"A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)". irct.ir. 2021-08-02. IRCT20150303021315N24. สืบค้นเมื่อ 2021-08-03.{{cite web}}:  CS1 maint: url-status (ลิงก์)
↑  
"Monovalent Recombinant COVID19 Vaccine (COVAX19)". ClinicalTrials.gov. 2020-07-01. NCT04453852. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  "A phase II, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)". Iranian Registry of Clinical Trials. สืบค้นเมื่อ 2021-05-28.
↑  
"GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 2021-01-07. NCT04528641.
↑  
"ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years". ReiThera Srl. Yahoo! Finance. 2020-11-24. สืบค้นเมื่อ 2021-01-12.
↑  
"Study of GRAd-COV2 for the Prevention of COVID-19 in Adults (COVITAR)". ClinicalTrials.gov. 2021-03-10. NCT04791423. สืบค้นเมื่อ 2021-03-20.
↑  
"ReiThera's COVID-19 vaccine candidate enters Phase 2/3 clinical study". ReiThera. 2021-03-18. สืบค้นเมื่อ 2021-03-20.
↑  "New ReiThera vaccine safe, response peak at 4 wks". ANSA. 2021-01-05.
↑  
"SK Bioscience Submitted Phase 3 IND for COVID-19 Vaccine". SK Bioscience.
↑  "A Phase III Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". ClinicalTrials.gov. 2021-08-17. NCT05007951. สืบค้นเมื่อ 2021-08-17.
↑  
"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 2021-02-11. NCT04750343. สืบค้นเมื่อ 2021-04-22.
↑  
"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 2021-02-08. NCT04742738. สืบค้นเมื่อ 2021-04-22.
↑  
Raghavan, Prabha (2021-06-05). "'At-risk' policy change: Govt puts money on new-platform Covid-19 vaccine". The Indian Express.
↑  
"A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry - India. 2021-01-13. CTRI/2020/11/029032. เก็บจากแหล่งเดิมเมื่อ 2020-11-12.
↑  
"CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. Coalition for Epidemic Preparedness Innovations. สืบค้นเมื่อ 2021-03-05.
↑  
Chui, M (2020-11-16). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine.
↑  
"Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine". The Hindu. 2021-04-24.
↑  "Biological E's CORBEVAX vaccine clinical study for protection against Covid-19 disease". ctri.nic.in. Clinical Trial Registry India. 2021-06-04. CTRI/2021/06/034014. สืบค้นเมื่อ 2021-06-09.
↑  
Leo, L (2020-11-16). "Biological E initiates human trials of vaccine". Mint.
↑  
"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-04-07. NCT04336410. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 2020-04-16. สืบค้นเมื่อ 2020-04-23.
↑  
Neumann, E; Schaefer-Ridder, M; Wang, Y; Hofschneider, PH (1982). "Gene transfer into mouse lyoma cells by electroporation in high electric fields". The EMBO Journal. 1 (7): 841–5. doi:10.1002/j.1460-2075.1982.tb01257.x. PMC 553119. PMID 6329708.
↑  
Chang, Donald C. (2006-09-15), "Electroporation and Electrofusion",  ใน Meyers, Robert A. (บ.ก.), Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley-VCH Verlag GmbH & Co. KGaA, doi:10.1002/3527600906.mcb.200300026, ISBN 9783527600908
↑  "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure". ClinicalTrials.gov. 2020-11-24. NCT04642638. สืบค้นเมื่อ 2021-03-12.
↑  "Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19". United States National Library of Medincine. สืบค้นเมื่อ 2021-03-12.
↑  "A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of COVID-19 DNA Vaccine INO-4800 Administered Intradermally Followed by Electroporation in Healthy Adult and Elderly Volunteers". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-03-20. สืบค้นเมื่อ 2021-03-27.
↑  
"Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. 2020-07-09. NCT04463472. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"Study of COVID-19 DNA Vaccine (AG0302-COVID19)". ClinicalTrials.gov. 2020-08-26. NCT04527081. สืบค้นเมื่อ 2021-03-11.
↑  
"About AnGes - Introduction". AnGes, Inc. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-01.
↑  "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". ClinicalTrials.gov. 2020-12-07. NCT04655625. สืบค้นเมื่อ 2021-03-11.
↑  
"Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)". ClinicalTrials.gov. 2021-08-04. NCT04990544. สืบค้นเมื่อ 2021-08-04.
↑  
"Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)". ClinicalTrials.gov. 2021-07-04. NCT04982068. สืบค้นเมื่อ 2021-07-29.
↑  "评价重组新型冠状病毒融合蛋白疫苗在健康人群安全性和免疫原性随机、双盲、安慰剂对照的I期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-05-03. สืบค้นเมื่อ 2021-04-21.
↑  "评价重组新型冠状病毒融合蛋白疫苗在健康人群免疫原性和安全性随机、双盲、安慰剂对照的II期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-05-03. สืบค้นเมื่อ 2021-04-21.
↑  "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-11-14. สืบค้นเมื่อ 2021-03-24.
↑  "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-05-03. สืบค้นเมื่อ 2021-03-24.
↑  
"A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. United States National Library of Medicine. 2020-11-01. NCT04608305.
↑  
"Phase 2b Dose-confirmatory Trial to Evaluate the Safety, Immunogenicity and Potential Efficacy of an VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE001)". ClinicalTrials.gov. 2021-07-29. NCT04990466. สืบค้นเมื่อ 2021-08-04.
↑  
"As Israel goes vaccine-wild, will the homegrown version lose its shot?". The Times of Israel. 2020-12-29. สืบค้นเมื่อ 2021-01-01.
↑  "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-05-25. สืบค้นเมื่อ 2021-04-22.
↑  
"Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 μg/200μl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. สืบค้นเมื่อ 2021-03-21.
↑  "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-06-16. สืบค้นเมื่อ 2021-06-15.